A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

November 2, 2024

Study Completion Date

November 2, 2024

Conditions
Glioblastoma
Interventions
RADIATION

Hypofractionated stereotactic radiation therapy

DRUG

Durvalumab

Trial Locations (10)

49055

Institut de Cancerologie de L'Ouest, Angers

67000

Centre Paul Strauss, Strasbourg

75013

Hopital Pitie Salpetriere, Paris

93 000

Hopital Avicenne, Bobigny

14 000

Centre Francois Baclesse, Caen

21 000

Centre Georges Francois Leclerc, Dijon

34 298

Institut Regional Du Cancer de Montpellier, Montpellier

92 210

Institut Curie, Saint-Cloud

Unknown

Institut Claudius Regaud, Toulouse

94 800

Institut Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Institut Claudius Regaud

OTHER